CTCs and circulating tumor-derived proteins have been used clinically including CA 19-9 and prostate-specific antigen (PSA) used for detecting and surveillance pancreatic cancer and prostate cancer, respectively. This evidence concerns the gene KLK3 and pancreatic neoplasm.